Safer nicotine wiki - User contributions [en-gb]

Heino Stover

2020-12-13T20:11:57Z

Bk13051: /* External Links */

__TOC__

=about=

Heino Stöver is a social scientist, PhD and Professor of Social Scientific Addiction Research at the Frankfurt University of Applied Sciences in Germany, Faculty of Health and Social Work.

=Biography=

Born: 17 March 1956 (age 64 years), Gödestorf, Syke, Germany

=Publications=

==Books==
''(ex.)''
* Heino Stöver (ed.): ''Die E-Zigarette: Geschichte – Gebrauch – Kontroversen.'' Fachhochschulverlag, Frankfurt am Main 2016, ISBN 978-3-943787-62-7.
* with F. L. Altice, L. Azbel et. al.: ''The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.'' In: ''The Lancet.'' Volume 388, No. 10050, 17. September 2016, S. 1228–1248.
* with I. I. Michels: ''Harm Reduction – from a conceptual framework to practical experience. The example of Germany.'' In: ''Substance Use & Misuse.'' 48, 2012, S. 1–12.
* with J. Pont and H. Wolff: ''Dual loyalty in prison health care: carry on or abolish?'' In: ''[[American Journal of Public Health]].'' Vol. 102, No. 3, März 2012, p. 475–480.
* with D. Schäffer (ed.): ''Drogen, HIV/AIDS, Hepatitis. Ein Handbuch''. Deutsche AIDS-Hilfe, Berlin 2011. ([http://www.aidshilfe.de/sites/default/files/_Broschuere_Drogenhandbuch.pdf Broschüre] (PDF; 3,8<span class="mw_htmlentity"></span>MB))
* with K. Thane: ''Towards a continuum of care in the EU criminal justice system. A survey of prisoners’ needs in four countries (Estonia, Hungary, Lithuania, Poland).'' (= Gesundheitsförderung im Justizvollzug. Band 20). BIS-Verlag, Oldenburg 2011, ISBN 978-3-8142-2233-2.
* ''Barriers to opioid substitution treatment access, entry and retention: A survey of opioid users, patients in treatment, and treating and non-treating physicians.'' In: ''European Addiction Research.'' 17, 2011, p. 44–54.
* with I. I. Michels: ''Drug use and opioid substitution treatment for prisoners.'' In: ''Harm Reduction Journal.'' 7, 2010, p. 17.

=External Links=

* [https://www.frankfurt-university.de/en/about-us/faculty-4-health-and-social-work/contacts-at-faculty-4/professors-at-faculty-4/heino-stover/ Prof. Heino Stöver's Page at the website of the Frankfurt University of Applied Sciences]
* [https://youtube.com/channel/UC-Kcgvz8dNU7cTrxP0Mhqqw Prof. Stöver's YouTube channel]
* [https://twitter.com/HeinoStoever Prof. Stöver at Twitter]

[[Category: People of note]]

Bernd Mayer

2020-12-13T20:08:10Z

Bk13051:

__TOC__

=about=

'''Bernhard-Michael Mayer''', also ''Bernd'' Mayer (* July 25 1959 in Graz) is an Austrian pharmacologist and toxicologist. He is a professor at the University of Graz, Austria.

Since 2005 he has been working on the health aspects of electronic cigarettes and is publicly committed to the acceptance of these products as a less harmful alternative to tobacco cigarettes, fighting pseudoscience in alternative medicine and its siblings in anti-vaping campaigns of tobacco control activists.

In September 2020 he published a popular science book on the subject.
<ref>''Die E-Zigarette: Fakten und Mythen.'' Delta X Verlag,
2020. ISBN 978-3-903229-22-8</ref>

=Career=
''(ex.)''
After his studies in chemistry and physics in Graz and his dissertation at the University Children's Hospital under the supervision of Hermann Esterbauer at the Institute for Biochemistry, was awarded a Dr. phil. PhD.

Since 1987 he first worked as a university assistant at the Institute for Pharmacodynamics and Toxicology, as well as research fellow of the Alexander von Humboldt Foundation and research assistant at the Institute for Pharmacology at the Free University of Berlin. He qualified as professor in biochemical pharmacology in Graz in 1991 where he was associate professor at the Institute for Pharmacology and Toxicology until 1998, and from 1997 to 2004 also headed the institute. In 1999 he was appointed full university professor of pharmacology and toxicology. From 1998 to 2002 Mayer headed the Graz section of the Austrian Society for Molecular Biosciences and Biotechnology. From 2003 to 2012 Mayer was a member of the board of trustees in the Biomed department of the Austrian Science Fund (FWF).

Since 2004 he has been head of the pharmacology and toxicology department at the then newly founded Institute for Pharmaceutical Sciences in Graz.

=Research=

Mayer's research concerns biological signal processing in blood vessels and in the heart. Its focus is on nitrogen monoxide (NO), NO synthases, cyclic GMP, oxidative stress, and organic nitrates.

Most notably,did he publish in 2014 a scientific research paper on the ''realistical'' lethal dose of [nicotine], ranging from ''500 to 1000 mg'' as the lower limit for the lethal effect of orally ingested nicotine in humans based on recent poisoning cases with documented blood plasma levels for nicotine.
He also identified the origins of the previously generally accepted lethal dose of nicotine (50–60 mg) in Rudolf Kobert's textbook on intoxications from 1906, which were based on questionable self-experiments in 1856 by the Viennese pharmacologist Karl Damian von Schroff.<ref>B. Mayer: ''How much nicotine kills a human? Tracing back the generally accepted lethal dose to dubious self-experiments in the nineteenth century.'' In: ''[[Archives of Toxicology]].'' Band 88, Nummer 1, Januar 2014, S. 5–7, [[DOI:10.1007/s00204-013-1127-0]].</ref>

=Publications=
<references />

=External Links=
* [https://online.uni-graz.at/kfu_online/visitenkarte.show_vcard?pPersonenId=1685563144368922&pPersonenGruppe=3 Prof. Mayer, business card from the University Graz]

* [https://www.youtube.com/channel/UC-OtjiFrsB2haZIvdEuNsSA Prof. Mayer's YouTube-Channel]

* [http://twitter.com/beli_erf Prof. Mayer on Twitter]

[[Category: People of note]]

Heino Stover

2020-12-13T19:09:17Z

Bk13051: /* Books */

__TOC__

=about=

Heino Stöver is a social scientist, PhD and Professor of Social Scientific Addiction Research at the Frankfurt University of Applied Sciences in Germany, Faculty of Health and Social Work.

=Biography=

Born: 17 March 1956 (age 64 years), Gödestorf, Syke, Germany

=Publications=

==Books==
''(ex.)''
* Heino Stöver (ed.): ''Die E-Zigarette: Geschichte – Gebrauch – Kontroversen.'' Fachhochschulverlag, Frankfurt am Main 2016, ISBN 978-3-943787-62-7.
* with F. L. Altice, L. Azbel et. al.: ''The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.'' In: ''The Lancet.'' Volume 388, No. 10050, 17. September 2016, S. 1228–1248.
* with I. I. Michels: ''Harm Reduction – from a conceptual framework to practical experience. The example of Germany.'' In: ''Substance Use & Misuse.'' 48, 2012, S. 1–12.
* with J. Pont and H. Wolff: ''Dual loyalty in prison health care: carry on or abolish?'' In: ''[[American Journal of Public Health]].'' Vol. 102, No. 3, März 2012, p. 475–480.
* with D. Schäffer (ed.): ''Drogen, HIV/AIDS, Hepatitis. Ein Handbuch''. Deutsche AIDS-Hilfe, Berlin 2011. ([http://www.aidshilfe.de/sites/default/files/_Broschuere_Drogenhandbuch.pdf Broschüre] (PDF; 3,8<span class="mw_htmlentity"></span>MB))
* with K. Thane: ''Towards a continuum of care in the EU criminal justice system. A survey of prisoners’ needs in four countries (Estonia, Hungary, Lithuania, Poland).'' (= Gesundheitsförderung im Justizvollzug. Band 20). BIS-Verlag, Oldenburg 2011, ISBN 978-3-8142-2233-2.
* ''Barriers to opioid substitution treatment access, entry and retention: A survey of opioid users, patients in treatment, and treating and non-treating physicians.'' In: ''European Addiction Research.'' 17, 2011, p. 44–54.
* with I. I. Michels: ''Drug use and opioid substitution treatment for prisoners.'' In: ''Harm Reduction Journal.'' 7, 2010, p. 17.

=External Links=

* [https://www.frankfurt-university.de/en/about-us/faculty-4-health-and-social-work/contacts-at-faculty-4/professors-at-faculty-4/heino-stover/ Prof. Heino Stöver's Page at the website of the Frankfurt University of Applied Sciences]
* [https://twitter.com/HeinoStoever Prof. Heino Stöver at Twitter]

[[Category: People of note]]

Heino Stover

2020-12-13T19:08:27Z

Bk13051: further additions

__TOC__

=about=

Heino Stöver is a social scientist, PhD and Professor of Social Scientific Addiction Research at the Frankfurt University of Applied Sciences in Germany, Faculty of Health and Social Work.

=Biography=

Born: 17 March 1956 (age 64 years), Gödestorf, Syke, Germany

=Publications=

==Books==
''(ex.)''
* Heino Stöver (Hrsg.): ''Die E-Zigarette: Geschichte – Gebrauch – Kontroversen.'' Fachhochschulverlag, Frankfurt am Main 2016, ISBN 978-3-943787-62-7.
* with F. L. Altice, L. Azbel et. al.: ''The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.'' In: ''The Lancet.'' Volume 388, No. 10050, 17. September 2016, S. 1228–1248.
* with I. I. Michels: ''Harm Reduction – from a conceptual framework to practical experience. The example of Germany.'' In: ''Substance Use & Misuse.'' 48, 2012, S. 1–12.
* with J. Pont and H. Wolff: ''Dual loyalty in prison health care: carry on or abolish?'' In: ''[[American Journal of Public Health]].'' Vol. 102, No. 3, März 2012, p. 475–480.
* with D. Schäffer (ed.): ''Drogen, HIV/AIDS, Hepatitis. Ein Handbuch''. Deutsche AIDS-Hilfe, Berlin 2011. ([http://www.aidshilfe.de/sites/default/files/_Broschuere_Drogenhandbuch.pdf Broschüre] (PDF; 3,8 MB))
* with K. Thane: ''Towards a continuum of care in the EU criminal justice system. A survey of prisoners’ needs in four countries (Estonia, Hungary, Lithuania, Poland).'' (= Gesundheitsförderung im Justizvollzug. Band 20). BIS-Verlag, Oldenburg 2011, ISBN 978-3-8142-2233-2.
* ''Barriers to opioid substitution treatment access, entry and retention: A survey of opioid users, patients in treatment, and treating and non-treating physicians.'' In: ''European Addiction Research.'' 17, 2011, p. 44–54.
* with I. I. Michels: ''Drug use and opioid substitution treatment for prisoners.'' In: ''Harm Reduction Journal.'' 7, 2010, p. 17.

=External Links=

* [https://www.frankfurt-university.de/en/about-us/faculty-4-health-and-social-work/contacts-at-faculty-4/professors-at-faculty-4/heino-stover/ Prof. Heino Stöver's Page at the website of the Frankfurt University of Applied Sciences]
* [https://twitter.com/HeinoStoever Prof. Heino Stöver at Twitter]

[[Category: People of note]]

Does vaping cause cancer?

2020-12-08T18:28:10Z

Bk13051: Created page with "The question, if nicotine without combustion acts carcinogenic can be - based on a plethora of research - easily be answered with NO. Nonetheless, there is a wide misconcepti..."

The question, if nicotine without combustion acts carcinogenic can be - based on a plethora of research - easily be answered with NO.

Nonetheless, there is a wide misconception and illiteracy about the safety and efficacy of nicotine, when it is consumed in non-combustible ways, despite decades long research and marketing efforts conducted by pharmaceutical companies in support of the introduction and sales or prescriptions of nicotine replacement therapies (NRTs) like nicotine gums or transdermal patches, lozenges, nasal and oral sprays or inhalers, that contain the same pharmaceutical graded nicotine derived from tobacco plants as modern smokefree nicotine products like nicotine pouches or nicotine vaping product (which do contain extracted nicotine but not further processed tobacco plant materials).

It is meanwhile an established scientific consensus, that the byproducts in the inhaled smoke from burned tobacco leafs are the main contributors to smoking-related diseases, but not nicotine.
Though there is no combustion, specific components (e.g. nitrosamines) in orally used smokeless tobacco leaf products that may contribute to certain type of oral cancer, but depend heavily on the specific treatment and type of consumption (see differences between Swedish snus and other orally used tobacco products).

Epidemiological studies of NRTs and Swedish snus have shown that smokeless nicotine consumption does not increase a users’s risk for developing tobacco (smoking) related diseases in comparison to non-users.

Nonetheless, for users with pre-existing conditions, the benign short-timed effects of nicotine on e.g. the cardiovascular or the digestive system, through its likewise stimulating and relaxing effects on both the para- and sympathetic nervous system should be taken into consideration.
This goes likewise for users with diagnosed cancerous tumors, as some research indicates, that nicotin may support the grows of bloods vessels around those tumors.

But although not completely risk-free (an unscientific demand, which cannot be fulfilled by any other human kind of behaviour), the complete switch from consumption of combusted to smokeless nicotine offers a plethora of health benefits.

Research indicates, that the lifelong risk for cancerous diseases from using nicotine without combustion, e.g. with nicotine vaping products does not exceed 0.5% of that caused by the use of combusted tobacco products, meaning it's over 200 times less riskier.

Widespread misconceptions even among medical personal and practitioners about the benignity of smokeless nicotine are likely caused by decades of zealous campaigning from well funded anti-tobacco pressure groups, which despite all scientific evidence treat all tobacco and nicotine products equally harmful in regards of potential, especially when compared to cigarettes.